使用PET对接受免疫治疗的实体瘤患者疗效预测
Journal: Frontier Forum of Clinical Medicine DOI: 10.12238/ffcr.v2i4.10377
Abstract
在多种恶性肿瘤治疗中,检查点抑制剂已成为一线疗法,但仅部分患者受益,推动了生物标志物研究的发展。正电子发射断层扫描(Positron Emission Tomography, PET)作为分子影像技术用于评估生物标志物。目前研究主要集中于常规的18F-FDG PET和针对PD-(L)1的专用PET示踪剂的预测能力,同时也在探索人工智能在预测治疗反应方面的潜力。但是由于检查点抑制剂的反应模式与传统化疗存在显著差异,使得评估治疗效果面临诸多挑战。而且PET技术为早期反应评估提供了重要信息,有助于区分完全反应与残留病变,从而指导治疗方案的调整。
Keywords
免疫疗法；正电子发射计算机断层扫描；非小细胞肺癌；黑色素瘤；生物标志物
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Grizzi F, Castello A, Lopci E. Is it time to change our vision of tumor metabolism prior to immunotherapy? [J]. Eur J Nucl Med Mol Imaging,2018,45(6):1072-5.
[2] Takada K, Toyokawa G, Yoneshima Y, et al. 18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer[J].Scientific reports,2019,9(1).
[3] Seban R D, Mezquita L, Berenbaum A, et al. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors[J].European journal of nuclear medicine and molec ular imaging, 2020,47(5):1147-57.
[4] Chae S Y, Ahn S H, Kim S B, et al. Diagnostic accuracy and safety of 16α-[(18)F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study [J]. The Lancet Oncology, 2019, 20(4): 546-55.
[5] Na F, Wang J, Li C, et al. Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radioth erapy:meta-analysis[J].Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2014,9(6):834-42.
[6] Niemeijer A N, Leung D, Huisman M C, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer[J].Nature communications, 2018,9(1):4664.
[7] Ito K, Teng R, Schöder H, et al. (18)F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma[J].Journal of nuclear medicine: official publication, Society of Nuclear Medicine,2019,60(3):335-41.
[8] Tan A C, Emmett L, Lo S, et al. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma [J]. Annals of oncology : official journal of the European Society for Medical Oncology,2018,29(10):2115-20.
[9] Anwar H,Sachpekidis C, Winkler J, et al. Absolute number of new lesions on (18)F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab [J]. Eur J Nucl Med Mol Imaging, 2018,45(3):376-83.
[2] Takada K, Toyokawa G, Yoneshima Y, et al. 18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer[J].Scientific reports,2019,9(1).
[3] Seban R D, Mezquita L, Berenbaum A, et al. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors[J].European journal of nuclear medicine and molec ular imaging, 2020,47(5):1147-57.
[4] Chae S Y, Ahn S H, Kim S B, et al. Diagnostic accuracy and safety of 16α-[(18)F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study [J]. The Lancet Oncology, 2019, 20(4): 546-55.
[5] Na F, Wang J, Li C, et al. Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radioth erapy:meta-analysis[J].Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2014,9(6):834-42.
[6] Niemeijer A N, Leung D, Huisman M C, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer[J].Nature communications, 2018,9(1):4664.
[7] Ito K, Teng R, Schöder H, et al. (18)F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma[J].Journal of nuclear medicine: official publication, Society of Nuclear Medicine,2019,60(3):335-41.
[8] Tan A C, Emmett L, Lo S, et al. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma [J]. Annals of oncology : official journal of the European Society for Medical Oncology,2018,29(10):2115-20.
[9] Anwar H,Sachpekidis C, Winkler J, et al. Absolute number of new lesions on (18)F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab [J]. Eur J Nucl Med Mol Imaging, 2018,45(3):376-83.
Copyright © 2024 顾章媛, 莊志刚
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License